Author:
Sondhi Dolan,Crystal Ronald G.,Kaminsky Stephen M.
Reference61 articles.
1. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol Histopathol. 2004;19:535–64.
2. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3–14.
3. Williams RE, Gottlob I, Lake BD, Goebel HH, Winchester BG, Wheeler RB. CLN2 classic late infantile NCL. In: Goebel HH, editor. The neuronal ceroid lipofuscinoses (Batten disease). Amsterdam: IOS Press; 1999. p. 37–53.
4. Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, Lobel P. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science. 1997;277:1802–5.
5. Sleat DE, Gin RM, Sohar I, Wisniewski K, Sklower-Brooks S, Pullarkat RK, Palmer DN, Lerner TJ, Boustany RM, Uldall P, Siakotos AN, Donnelly RJ, Lobel P. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet. 1999;64:1511–23.